Brain Tumor - Drug Pipeline Analysis and Market Forecasts to 2016

The Brain Tumor Market is Forecast to Show Positive Growth to 2016

Online PR News – 23-January-2010 – – GlobalData has estimated the global brain tumor market to be worth $1,094m in 2009 and forecasts it to grow at a CAGR of 3.1% for the next seven years to reach $1.3 billion by 2016. An increasing number of novel therapies are expected to launch in this period and this will act as a significant driver for the market. There are currently three products approved for the treatment of brain tumors, and there is a strong potential opportunity for pipeline products to enter this market.

For further details, please click or add the below link to your browser:

GlobalData finds that the current marketed products seem to be not satisfying the unmet needs that exist in the brain tumor market. The current market has huge potential for pipeline drugs that are strong in terms of survival, efficacy, and safety. As patients become more aware of the latest technological developments, increased efficacy, tolerability, and safety profiles will be the key factors that drive the acceptance and market penetration of pipeline products. As the marketed products do not serve the unmet need, the market continues to offer opportunities for stronger pipeline candidates. Considering the fact that the majority of pipeline products are combination and first-in-class therapies with proven superiority in offering therapeutic performance, the existing market leaders will face significant challenges in maintaining their market shares.

GlobalData expects that Myriad Genetics, Merck Sereno, Merck, F.Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, GlaxoSmithKline and others will become the leading competitors in the global brain tumor market. These companies have some of the most technologically advanced products in their pipeline portfolios and are expected to attract the investor attention in the coming years.
The competition in the existing market is not intense with only three key products approved. This scenario could change in the near future following multiple product launches by the leading and emerging manufacturers who are concentrating on novel therapies.

For further details, please click or add the below link to your browser:

GlobalData’s analysis shows that products for the treatment of brain tumors in the developmental pipeline are strong with 185 molecules in various phases of clinical development including 73 first-in-class molecules. These first-in-class molecules have distinct advantages over the current marketed products in terms of higher survival rates, better efficacy and safety profiles, and to the extent that they satisfy the unmet needs in the market. If approved, these products will lead to intense competition in the race to produce blockbuster drugs.

GlobalData, the industry analysis specialist’s new report, “Brain Tumor - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global brain tumor market. The report identifies the key trends shaping and driving the dynamism in the global brain tumor market. The report also provides insight on the prevalent competitive landscape and the emerging players that are expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global brain tumor market.

For further details, please click or add the below link to your browser:

Or Visit our report store: